Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057569626> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2057569626 endingPage "119" @default.
- W2057569626 startingPage "111" @default.
- W2057569626 abstract "Modern treatment protocols lead to complete remission (CR) in a considerable proportion of patients with lymphoproliferative disorders. However, many of these patients ultimately relapse, implying that achievement of a clinical CR is compatible with significant amounts of residual malignant cells. Cytogenetic, molecular and immunological techniques that are more sensitive than morphology are increasingly used to assess and quantify minimal residual disease (MRD). Immunological marker analysis allows the detection of aberrant or unusual immunophenotypes, PCR techniques target fusion regions of chromosome aberrations and clone-specific immunoglobulin and T-cell receptor gene rearrangements. The rationale underlying MRD studies is to improve measurement of treatment response, to provide independent prognostic information and to optimise therapeutic strategies. In acute lymphoblastic leukemia (ALL), the MRD based evaluation of initial response to front-line therapy emerged as a highly relevant diagnostic tool, particularly in childhood ALL, where MRD has been shown to be an independent prognostic factor allowing a precise risk group classification. In patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) the prognostic significance of MRD is still a matter of debate, as the majority of patients remain MRD positive after conventional treatment. This phenomenon has changed with the implementation of new treatment modalities, such as application of monoclonal antibodies, where a significant proportion of patients with NHL converts to MRD negativity and experiences prolonged remission. Whether this molecular remission will translate into a superior overall survival is currently the goal of ongoing prospective studies." @default.
- W2057569626 created "2016-06-24" @default.
- W2057569626 creator A5035277761 @default.
- W2057569626 creator A5061380659 @default.
- W2057569626 creator A5071552171 @default.
- W2057569626 creator A5075073484 @default.
- W2057569626 date "2004-01-01" @default.
- W2057569626 modified "2023-10-10" @default.
- W2057569626 title "Significance of Minimal Residual Disease in Lymphoid Malignancies" @default.
- W2057569626 cites W1986395681 @default.
- W2057569626 cites W1996838280 @default.
- W2057569626 cites W2008278623 @default.
- W2057569626 cites W2019471283 @default.
- W2057569626 cites W2099867002 @default.
- W2057569626 cites W2110725223 @default.
- W2057569626 cites W2116249739 @default.
- W2057569626 cites W2129285584 @default.
- W2057569626 cites W2134793460 @default.
- W2057569626 cites W2140864225 @default.
- W2057569626 cites W2144010959 @default.
- W2057569626 cites W2147572934 @default.
- W2057569626 cites W2151069914 @default.
- W2057569626 cites W2313577290 @default.
- W2057569626 cites W2323369629 @default.
- W2057569626 cites W4241904210 @default.
- W2057569626 doi "https://doi.org/10.1159/000077566" @default.
- W2057569626 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15179011" @default.
- W2057569626 hasPublicationYear "2004" @default.
- W2057569626 type Work @default.
- W2057569626 sameAs 2057569626 @default.
- W2057569626 citedByCount "24" @default.
- W2057569626 countsByYear W20575696262014 @default.
- W2057569626 countsByYear W20575696262016 @default.
- W2057569626 countsByYear W20575696262017 @default.
- W2057569626 crossrefType "journal-article" @default.
- W2057569626 hasAuthorship W2057569626A5035277761 @default.
- W2057569626 hasAuthorship W2057569626A5061380659 @default.
- W2057569626 hasAuthorship W2057569626A5071552171 @default.
- W2057569626 hasAuthorship W2057569626A5075073484 @default.
- W2057569626 hasConcept C104317684 @default.
- W2057569626 hasConcept C126322002 @default.
- W2057569626 hasConcept C143998085 @default.
- W2057569626 hasConcept C203014093 @default.
- W2057569626 hasConcept C2778461978 @default.
- W2057569626 hasConcept C2779134260 @default.
- W2057569626 hasConcept C2779338263 @default.
- W2057569626 hasConcept C2779823535 @default.
- W2057569626 hasConcept C55493867 @default.
- W2057569626 hasConcept C71924100 @default.
- W2057569626 hasConcept C81089528 @default.
- W2057569626 hasConcept C86803240 @default.
- W2057569626 hasConceptScore W2057569626C104317684 @default.
- W2057569626 hasConceptScore W2057569626C126322002 @default.
- W2057569626 hasConceptScore W2057569626C143998085 @default.
- W2057569626 hasConceptScore W2057569626C203014093 @default.
- W2057569626 hasConceptScore W2057569626C2778461978 @default.
- W2057569626 hasConceptScore W2057569626C2779134260 @default.
- W2057569626 hasConceptScore W2057569626C2779338263 @default.
- W2057569626 hasConceptScore W2057569626C2779823535 @default.
- W2057569626 hasConceptScore W2057569626C55493867 @default.
- W2057569626 hasConceptScore W2057569626C71924100 @default.
- W2057569626 hasConceptScore W2057569626C81089528 @default.
- W2057569626 hasConceptScore W2057569626C86803240 @default.
- W2057569626 hasIssue "1-2" @default.
- W2057569626 hasLocation W20575696261 @default.
- W2057569626 hasLocation W20575696262 @default.
- W2057569626 hasOpenAccess W2057569626 @default.
- W2057569626 hasPrimaryLocation W20575696261 @default.
- W2057569626 hasRelatedWork W1524590520 @default.
- W2057569626 hasRelatedWork W1697705604 @default.
- W2057569626 hasRelatedWork W2017092658 @default.
- W2057569626 hasRelatedWork W2099866477 @default.
- W2057569626 hasRelatedWork W2371792548 @default.
- W2057569626 hasRelatedWork W2377327490 @default.
- W2057569626 hasRelatedWork W2412288087 @default.
- W2057569626 hasRelatedWork W2419862115 @default.
- W2057569626 hasRelatedWork W2770713575 @default.
- W2057569626 hasRelatedWork W2560253012 @default.
- W2057569626 hasVolume "112" @default.
- W2057569626 isParatext "false" @default.
- W2057569626 isRetracted "false" @default.
- W2057569626 magId "2057569626" @default.
- W2057569626 workType "article" @default.